文献速递支持与姑息治疗

芬太尼舌下片对比皮下吗啡治疗阿片类药物治疗中重度癌痛发作:双盲随机非劣效性试验

Fentanyl Sublingual Tablets Versus Subcutaneous Morphine for the Management of Severe Cancer Pain Episodes in Patients Receiving Opioid Treatment: A Double-Blind, Randomized, Noninferiority Trial.
PubMed 文献 · J Clin Oncol · 2017-01-23

本研究为双盲双模拟随机非劣效性试验,纳入114例接受稳定阿片类治疗并出现重度疼痛发作的癌痛患者,随机分入芬太尼舌下片100 μg组(n=58)或皮下吗啡5 mg组(n=56)。主要终点为给药后10、20、30分钟的平均疼痛强度,非劣效界值设为-0.6。结果显示芬太尼舌下片未在预设界值内证明非劣效于皮下吗啡,两组安全性均良好,93%患者偏好舌下给药途径。

要点

  • 芬太尼舌下片100 μg对比皮下吗啡5 mg,给药后30分钟内平均疼痛强度差值95%CI上限超过预设非劣效界值-0.6。
  • 芬太尼舌下片组30分钟后追加第二剂的患者比例高于皮下吗啡组(51% vs 37%)。
  • 两种治疗均耐受良好,93%患者偏好舌下给药途径。

核心结论

  • 本试验未在预设非劣效界值内证明芬太尼舌下片非劣效于皮下吗啡。
  • 两种治疗均安全,患者偏好舌下给药途径。
  • 与皮下吗啡相比,芬太尼舌下片提供镇痛但存在轻度至中度疗效降低的风险。

研究设计与样本

  • 双盲、双模拟、随机非劣效性试验。
  • 纳入接受稳定阿片类药物治疗并出现重度疼痛发作的患者,随机分入芬太尼舌下片100 μg组(n=58)或皮下吗啡5 mg组(n=56)。
  • 芬太尼舌下片组1例在给药前撤回知情同意,被排除分析。
  • 主要终点为给药后10、20、30分钟用0至10数字评定量表评估的平均疼痛强度,采用以基线疼痛强度校正的协方差分析。
  • 组间差异的非劣效界值设为-0.6,等于最小临床重要疼痛强度差值2分的三分之一。

主要发现

  • 两组基线平均疼痛强度均为7.5。
  • 给药后10、20、30分钟的平均疼痛强度:芬太尼舌下片组为5.0,皮下吗啡组为4.5,组间差异-0.49(95%CI,-1.10至0.09),95%CI包括非劣效界值。
  • 芬太尼舌下片组30分钟后接受第二剂药物的患者比例高于皮下吗啡组(51% vs 37%;风险差-13%;95%CI,-30%至3%)。
  • 两种治疗均耐受良好,平均随访不良事件评分低于「有一点」的反应水平。
  • 93%的患者偏好舌下给药途径。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Fentanyl sublingual tablets (FST) are a potentially useful alternative to parenteral opioids such as subcutaneous morphine (SCM) to treat severe cancer pain episodes. No direct comparison between FST and SCM is available. The aim of this study was to test noninferiority of FST versus SCM during the first 30 min postadministration. Methods Patients receiving stable opioid therapy and experiencing a severe pain episode were randomly assigned to either 100 µg FST or 5 mg SCM in a double-blind, double-dummy trial. Average pain intensity (PI) assessed on a 0 to 10 numerical rating scale at 10, 20, and 30 min postadministration was the main end point. Analysis of covariance, adjusted by baseline PI, was the main analysis. The noninferiority margin (NIm) for the between-group difference was set at -0.6, that is, equal to one third of the minimum clinically important PI difference of two points. Results A total of 114 patients were randomly assigned to either FST (n = 58) or SCM (n = 56). One patient (in the FST group) withdrew consent before drug administration and was excluded from analysis. Baseline mean PIs were 7.5 in both groups; mean average PIs assessed at 10, 20, and 30 min postadministration were 5.0 and 4.5 for FST and SCM, respectively, with the 95% CI of the between-group difference including the NIm (-0.49; 95% CI, -1.10 to 0.09). Patients taking FST received a second drug dose after 30 min more frequently than did patients taking SCM (51% v 37%, respectively; risk difference, -13%; 95% CI, -30% to 3%). Both treatments were well tolerated, with average follow-up adverse event scores below the response of "A Little." Ninety-three percent of patients preferred the sublingual administration. Conclusion This trial did not show noninferiority of FST versus SCM within the chosen NIm. Both treatments were safe, and patients preferred the sublingual route of administration. FST provides analgesia with modest to moderate increased risk of lower efficacy compared with SCM.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Zecca E, Brunelli C, Centurioni F, et al. Fentanyl Sublingual Tablets Versus Subcutaneous Morphine for the Management of Severe Cancer Pain Episodes in Patients Receiving Opioid Treatment: A Double-Blind, Randomized, Noninferiority Trial. J Clin Oncol. 2017. PMID: 28113021. doi:10.1200/JCO.2016.69.9504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。